United Nation AIDS Programme (UNAIDS): UNAIDS Report on the Global AIDS Epidemic 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (Last accessed November15, 2014).
2.
ZhouJ, KumarasamyN, DitangcoR, et al.The TREAT Asia HIV Observational Database: Baseline and retrospective data. J Acquir Immune Defic Syndr, 2005; 38:174–179.
3.
CornellM, MyerL, KaplanR, et al.The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Intl Health, 2009; 14:722–731.
4.
AlibhaiA, KippW, SaundersLD, et al.Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. Intl J Women's Health, 2010; 2:45–52.
5.
Le CoeurS, CollinsIJ, PannetierJ, et al.Gender and access to HIV testing and antiretroviral treatments in Thailand: Why do women have more and earlier access?. Soc Sci Med, 2009; 69:846–853.
6.
WenY, ZhaoD, DouZ, et al.Some patient-related factors associated with late access to ART in China's free ART program. AIDS Care, 2011; 23:1226–1235.
7.
CurrierJS, SpinoC, GrimesJ, et al.Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr, 2000; 24:316–324.
8.
UmehOC, CurrierJC. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol, 2006; 2:273–283.
9.
ClarkR. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf, 2005; 28:1075–1083.
10.
FloridiaM, GiulianoM, PalmisanoL, et al.Gender differences in the treatment of HIV infection. Pharmacol Res, 2008; 58:173–182.
11.
GandhiM, AweekaF, GreenblattRM, et al.Sex differences in pharmacokinetics and pharmacodynamics. Ann Rev Pharmacol Toxicol, 2004; 44:499–523.
